Development Overview

A Diversified portfolio

Incannex currently has 3 lead drug candidates and multiple secondary assets, whose proof of concept has been established in either pre-clinical, phase 1 or phase 2 clinical studies. With the growth of these diverse programs, Incannex is well positioned as a leader in the development of novel cannabinoid pharmaceuticals and psychedelic therapies. With 9 active development programs, Incannex is targeting conditions for patients with unmet medical needs.
development-overview-portfolio;

Our Active Trials

Pre Clinical
CanQuit Addiction Tobacco Smoking Cessation
CannQuit-O Opioid Addiction
ReneCann Vitiligo, Psoriasis, Eczema
Phase 2A
PSI-GAD Psilocybin for anxiety
IHL-675A Rheumatoid Arthritis
Phase 2B
IHL-42X Obstructive Sleep Apnoea

3 lead drug candidates and multiple secondary assets, with 1 primary goal – alleviate human suffering.

View our full assets directory below. Click on the asset to reveal its full details including: Addressable Market, Development Stage, Regulatory Development Stage, Next Steps and Relevant Patents.

Download Project List

IHL-42X Obstructive Sleep Apnoea
Addressable Market Opportunity (in US$)
$8.24B (U.S.) by 2024
Stage of Development
Phase 2/3 underway
Regulatory Stage of Development
Phase 2/3 trial completed
Next Steps
IND opening study
Relevant Patents
10x Pending, Key claims deemed novel & inventive
IHL-675A Rheumatoid Arthritis
Addressable Market Opportunity (in US$)
$60.1B (U.S.) in 2021
Stage of Development
Phase 2 completed
Regulatory Stage of Development
FDA Pre-IND completed
Next Steps
Complete phase 2 CT
Relevant Patents
16x Pending, Key claims deemed novel & inventive
PSI-GAD Psilocybin for anxiety
Addressable Market Opportunity (in US$)
$4.26B (U.S.) by 2033, 9% CAGR
Stage of Development
Phase 2A
Regulatory Stage of Development
FDA IND submission
Next Steps
Complete phase 2B
Relevant Patents
Provisional patents filed
IHL-675A Inflammatory Bowel Disease
Addressable Market Opportunity (in US$)
$21B (U.S.) in 2021
Stage of Development
Pre-clinical completed
Regulatory Stage of Development
FDA Pre-IND completed
Next Steps
Commence phase 2 CT
Relevant Patents
16x Pending, Key claims deemed novel & inventive
APIRx-1601 Skin: Vitiligo
Addressable Market Opportunity (in US$)
$0.1B (Global) in 2021
Stage of Development
Phase 2 completed
Regulatory Stage of Development
Pre-IND drafting
Next Steps
Phase 1
Relevant Patents
1x Granted, 1x Pending
APIRx-1602 Skin: Psoriasis
Addressable Market Opportunity (in US$)
$0.5B (Global) in 2021
Stage of Development
Phase 2A completed
Regulatory Stage of Development
Pre-IND drafting
Next Steps
Phase 1
Relevant Patents
2x Pending
APIRx-1603 Skin: Atopic Dermatitis
Addressable Market Opportunity (in US$)
$1.1B (Global) in 2021
Stage of Development
Phase 2A completed
Regulatory Stage of Development
Pre-IND drafting
Next Steps
Phase 1
Relevant Patents
1x Granted, 1x Pending
CanQuit Addiction Tobacco Smoking Cessation
Addressable Market Opportunity (in US$)
$47.75B (Global) by 2024, 17.3% CAGR
Stage of Development
Pre-clinical
Regulatory Stage of Development
Pre-regulatory
Next Steps
Phase 1
Relevant Patents
3x Granted
CannQuit-O Opioid Addiction
Addressable Market Opportunity (in US$)
$64B (U.S.) in 2021
Stage of Development
Pre-clinical
Regulatory Stage of Development
Pre-regulatory
Next Steps
Phase 1
Relevant Patents
2x Granted
IHL-675A Inflammatory Lung Disease
Addressable Market Opportunity (in US$)
$36.7B (U.S.) (COPD and Asthma) in 2022
Stage of Development
Pre-clinical completed
Regulatory Stage of Development
FDA Pre-IND completed
Next Steps
Commence phase 2 CT
Relevant Patents
2x Pending, Deemed novel & inventive
IHL-216A Concussion and TBI
Addressable Market Opportunity (in US$)
$3.46B (U.S.) in 2022
Stage of Development
Pre-clinical completed
Regulatory Stage of Development
FDA Pre-IND scheduled (Sept. 2022)
Next Steps
IND opening study
Relevant Patents
1x Granted, 6x Pending
MedChew™-1401 Pain and Spasticity in Multiple Sclerosis
Addressable Market Opportunity (in US$)
$62B (Global) in 2021
Stage of Development
Pre-clinical
Regulatory Stage of Development
Pre-IND completed in NL and Switzerland
Next Steps
Phase 1
Relevant Patents
Granted
MedChew™ GB Post-herpatic Neuralgia
Addressable Market Opportunity (in US$)
$3.7B (U.S.) by 2027
Stage of Development
Pre-clinical
Regulatory Stage of Development
FDA Pre-IND
Next Steps
Phase 1
Relevant Patents
Granted
MedChew™-1502 Parkinson's Disease
Addressable Market Opportunity (in US$)
$8.05B (Global) by 2027, 6.5% CAGR
Stage of Development
Pre-clinical
Regulatory Stage of Development
FDA Pre-IND
Next Steps
Phase 1
Relevant Patents
Granted
MedChew™-1503 Dementia
Addressable Market Opportunity (in US$)
$23.9B (Global) by 2028, 7.9% CAGR
Stage of Development
Pre-clinical
Regulatory Stage of Development
FDA Pre-IND
Next Steps
Phase 1
Relevant Patents
Granted
MedChew™ RL Restless Legs Syndrome
Addressable Market Opportunity (in US$)
12.1.% prevalence of U.S. pop.
Stage of Development
Pre-clinical
Regulatory Stage of Development
FDA Pre-IND
Next Steps
Phase 1
Relevant Patents
Granted
MedChew™ Dronabinol Nausea and Vomiting in Chemotherapy
Addressable Market Opportunity (in US$)
$3.1B (Global) by 2024
Stage of Development
Phase 1A completed
Regulatory Stage of Development
FDA Pre-IND completed
Next Steps
Phase 1B
Relevant Patents
Granted
APIRx 1505 Flotex Gastro: Chrohn's Disease
Addressable Market Opportunity (in US$)
$12.6B (Global) by 2024
Stage of Development
Pre-clinical
Regulatory Stage of Development
Pre-regulatory
Next Steps
Phase 1
Relevant Patents
Drafting
CanChew Plus Gastro: IBS
Addressable Market Opportunity (in US$)
$40B (U.S.) in 2021
Stage of Development
Phase 2A Completed
Regulatory Stage of Development
Pre-IND, ethical approval
Next Steps
Phase 2B
Relevant Patents
Granted
CanChew RX Gastro: IBD
Addressable Market Opportunity (in US$)
$2.78B (U.S.) by 2028
Stage of Development
Pre-clinical
Regulatory Stage of Development
Pre-regulatory
Next Steps
Phase 1
Relevant Patents
Granted
SuppoCan (Suppository) Gastro: IBD
Addressable Market Opportunity (in US$)
$2.78B (U.S.) by 2028
Stage of Development
Pre-clinical
Regulatory Stage of Development
Pre-regulatory
Next Steps
Phase 1
Relevant Patents
Granted
CheWell Addiction: Cannabis Dependence
Addressable Market Opportunity (in US$)
$64B (U.S.) in 2021
Stage of Development
Pre-clinical
Regulatory Stage of Development
Pre-IND ready for submission
Next Steps
Phase 1
Relevant Patents
Drafting
APIRx-1701 Opth: Glaucoma
Addressable Market Opportunity (in US$)
$10.4B (Global) by 2026, 6.3% CAGR
Stage of Development
Pre-clinical
Regulatory Stage of Development
Pre-regulatory
Next Steps
In vitro studies
Relevant Patents
Granted
APIRx-1702 Opth: Dry Eye Syndrome
Addressable Market Opportunity (in US$)
$6.6B (Global) by 2027, 6.4% CAGR
Stage of Development
Pre-clinical
Regulatory Stage of Development
Pre-regulatory
Next Steps
In vitro studies
Relevant Patents
Granted
APIRx-1801 Ultrapure THC
Addressable Market Opportunity (in US$)
$31.5B (Global) by 2030, 18.6% CAGR
Stage of Development
Developed
Regulatory Stage of Development
Developed
Next Steps
Relevant Patents
Granted
APIRx-1802 Ultrapure CBD
Addressable Market Opportunity (in US$)
$31.5B (Global) by 2030, 18.6% CAGR
Stage of Development
Developed
Regulatory Stage of Development
Next Steps
Relevant Patents
Granted
APIRx-1803 Ultrapure CBG
Addressable Market Opportunity (in US$)
$31.5B (Global) by 2030, 18.6% CAGR
Stage of Development
Developed
Regulatory Stage of Development
Next Steps
Relevant Patents
Granted

Key Benfits

1
Established drug formulations with data packages necessary for regulatory applications.
2
Proof of concept data from pre-clinical and clinical studies supporting the proposed therapeutic applications.
3
Regulatory filings for multiple drug products.
4
Granted and pending patents for manufacturing methods, drug formulations and methods of use to treat a range of conditions. Covering the entire drug development process from raw materials to patient dosing.
5
Different cannabinoid development strategy than IHL’s current programs.

Subscribe and stay connected

Stay up to date with Incannex’s leading research and development programs, multiple secondary assets, investor relations and biotechnology advancements.

"*" indicates required fields